Company news

ImmuneOnco Biopharmaceuticals (Shanghai) Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Proposed change of auditor

October 28, 2026

Next Day Disclosure Return

October 22, 2026

Next Day Disclosure Return

October 14, 2026

Next Day Disclosure Return

October 13, 2026

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September, 2026

October 6, 2026

Next Day Disclosure Return

September 29, 2026

Voluntary announcement - completion of capital Increase of a subsidiary

September 28, 2026

2026 Interim Report

September 28, 2026

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

July 31, 2025

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

May 23, 2025

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

May 22, 2025

Decks

The 5 newest of 11 decks. Every deck is listed under its year.